Peptris Technologies
Peptris Technologies accelerates preclinical drug discovery by using AI to design, rank, and prioritize molecules with reduced wet-lab testing. The company operates an automated pipeline that combines unsupervised learning and generative AI models (including neural networks and large language model techniques) to prune purchasable compound libraries, generate de novo variants, and predict potency, safety, selectivity, and clinical activity. Peptris focuses on novel chemical entities, drug repurposing, and rescuing clinically safe molecules across oncology, inflammation, and rare diseases. The platform is delivered as an AI-driven discovery service partnering with academia, biotech, and pharmaceutical companies. Peptris generates revenue through licensing, milestone payments, and royalties while operating a primarily virtual research model.
Peptris Technologies
Peptris Technologies accelerates preclinical drug discovery by using AI to design, rank, and prioritize molecules with reduced wet-lab testing. The company operates an automated pipeline that combines unsupervised learning and generative AI models (including neural networks and large language model techniques) to prune purchasable compound libraries, generate de novo variants, and predict potency, safety, selectivity, and clinical activity. Peptris focuses on novel chemical entities, drug repurposing, and rescuing clinically safe molecules across oncology, inflammation, and rare diseases. The platform is delivered as an AI-driven discovery service partnering with academia, biotech, and pharmaceutical companies. Peptris generates revenue through licensing, milestone payments, and royalties while operating a primarily virtual research model.